177 related articles for article (PubMed ID: 35779123)
21. Can cannabis kill? Characteristics of deaths following cannabis use in England (1998-2020).
Rock KL; Englund A; Morley S; Rice K; Copeland CS
J Psychopharmacol; 2022 Dec; 36(12):1362-1370. PubMed ID: 35946604
[TBL] [Abstract][Full Text] [Related]
22. Cannabis- and Substance-Related Epidemiological Patterns of Chromosomal Congenital Anomalies in Europe: Geospatiotemporal and Causal Inferential Study.
Reece AS; Hulse GK
Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141481
[TBL] [Abstract][Full Text] [Related]
23. Patterns of Cannabis- and Substance-Related Congenital General Anomalies in Europe: A Geospatiotemporal and Causal Inferential Study.
Reece AS; Hulse GK
Pediatr Rep; 2023 Feb; 15(1):69-118. PubMed ID: 36810339
[TBL] [Abstract][Full Text] [Related]
24. Driving Under the Influence of Marijuana Versus Driving and Dying Under the Influence of Marijuana: A Comparison of Blood Concentrations of Δ9-Tetrahydrocannabinol, 11-Hydroxy-Δ9-Tetrahydrocannabinol, 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol and Other Cannabinoids in Arrested Drivers Versus Deceased Drivers.
Lemos NP; San Nicolas AC; Volk JA; Ingle EA; Williams CM
J Anal Toxicol; 2015 Oct; 39(8):588-601. PubMed ID: 26378132
[TBL] [Abstract][Full Text] [Related]
25. Cannabis Teratology Explains Current Patterns of Coloradan Congenital Defects: The Contribution of Increased Cannabinoid Exposure to Rising Teratological Trends.
Reece AS; Hulse GK
Clin Pediatr (Phila); 2019 Sep; 58(10):1085-1123. PubMed ID: 31288542
[TBL] [Abstract][Full Text] [Related]
26. European epidemiological patterns of cannabis- and substance-related congenital cardiovascular anomalies: geospatiotemporal and causal inferential study.
Reece AS; Hulse GK
Environ Epigenet; 2022; 8(1):dvac015. PubMed ID: 35966825
[TBL] [Abstract][Full Text] [Related]
27. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination.
Robaina Cabrera CL; Keir-Rudman S; Horniman N; Clarkson N; Page C
Pulm Pharmacol Ther; 2021 Aug; 69():102047. PubMed ID: 34082108
[TBL] [Abstract][Full Text] [Related]
28. Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use.
Koch CD; Xu L; Curtis SA; Roberts JD; Bunch DR; El-Khoury JM
Clin Chim Acta; 2020 Nov; 510():515-521. PubMed ID: 32795544
[TBL] [Abstract][Full Text] [Related]
29. Impact of cannabinoids on pregnancy, reproductive health, and offspring outcomes.
Lo JO; Hedges JC; Girardi G
Am J Obstet Gynecol; 2022 Oct; 227(4):571-581. PubMed ID: 35662548
[TBL] [Abstract][Full Text] [Related]
30. Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation.
Russo EB; Spooner C; May L; Leslie R; Whiteley VL
Cannabis Cannabinoid Res; 2022 Jun; 7(3):336-344. PubMed ID: 34227878
[No Abstract] [Full Text] [Related]
31. Multivariate classification of cannabis chemovars based on their terpene and cannabinoid profiles.
Birenboim M; Chalupowicz D; Maurer D; Barel S; Chen Y; Fallik E; Paz-Kagan T; Rapaport T; Sadeh A; Kengisbuch D; Shimshoni JA
Phytochemistry; 2022 Aug; 200():113215. PubMed ID: 35483556
[TBL] [Abstract][Full Text] [Related]
32. Cannabidiol and Δ8-Tetrahydrocannabinol: Cannabinoids of Rising Interest and Concern.
White RM
Forensic Sci Rev; 2023 Jan; 35(1):27-45. PubMed ID: 36575371
[TBL] [Abstract][Full Text] [Related]
33. Extensive phytocannabinoid profiles of seized cannabis and cannabis-based medicines - Identification of potential distinguishing markers.
Scheunemann A; Elsner K; Germerott T; Hess C; Zörntlein S; Röhrich J
Forensic Sci Int; 2021 May; 322():110773. PubMed ID: 33839545
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
[TBL] [Abstract][Full Text] [Related]
35. Synaptic changes induced by cannabinoid drugs and cannabis use disorder.
Augustin SM; Lovinger DM
Neurobiol Dis; 2022 Jun; 167():105670. PubMed ID: 35219856
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
37. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
[TBL] [Abstract][Full Text] [Related]
38. Cannabinoid and substance relationships of European congenital anomaly patterns: a space-time panel regression and causal inferential study.
Reece AS; Hulse GK
Environ Epigenet; 2022; 8(1):dvab015. PubMed ID: 35145760
[TBL] [Abstract][Full Text] [Related]
39. Suppression of STAT3 Signaling by Δ9-Tetrahydrocannabinol (THC) Induces Trophoblast Dysfunction.
Chang X; Bian Y; He Q; Yao J; Zhu J; Wu J; Wang K; Duan T
Cell Physiol Biochem; 2017; 42(2):537-550. PubMed ID: 28578322
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.
Wiley JL; Marusich JA; Lefever TW; Grabenauer M; Moore KN; Thomas BF
Neuropharmacology; 2013 Dec; 75():145-54. PubMed ID: 23916483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
